<DOC>
	<DOCNO>NCT00878514</DOCNO>
	<brief_summary>The objective study demonstrate bioequivalence ( BE ) alprazolam 1 mg tablet XanaxÂ® 1 mg tablet feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>The study phase I , open , randomise , crossover , single dose pharmacokinetic study perform single centre . The study consist 2 treatment period , study subject receive test product reference product randomise order . During treatment period , study subject receive 1 mg alprazolam single oral dose administer high-calorie , high-fat meal . Following overnight fast least 10 hour , study subject eat standardised meal 30 minute prior administration study treatment . Blood sample draw treatment period . The duration study per subject approximately 5 week 9 week include screen visit , 2 treatment period wash-out study treatment administration post-treatment period .</detailed_description>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Written inform consent ( IC ) obtain Good general health ascertain detailed medical history , laboratory physical examination Finnish speaking male female , 1855 ( inclusive ) year age Normal body weight define body mass index &gt; 19 &lt; 30 kg/m2 ( BMI = weight/height2 ) Weight least 50 kg Regular intestinal transit ( recent history recurrent constipation , diarrhoea , intestinal problem ) Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological psychiatric disease Any condition require regular concomitant treatment ( include vitamin herbal product ) likely need concomitant treatment study Intake medication could affect outcome study . As exception , contraceptives intra uterine device ( IUD ) contain levonorgestrel hormonal implant allow . Any clinically significant abnormal laboratory value physical finding ( include electrocardiogram [ ECG ] vital sign ) may interfere interpretation test result cause health risk subject he/she participates study , judge investigator . Known hypersensitivity active substance ( ) excipients drug History vasovagal collapse History anaphylactic/anaphylactoid reaction History seizures include febrile seizure Pregnant lactate female Females childbearing potential use proper contraception ( IUD , hormonal implant surgical sterilization , spermicidal foam conjunction condom male partner ) ( Note : woman childbearing potential current sexual relationship include without contraception accord judgement investigator ) . Recent current ( suspect ) drug abuse positive result drug abuse test Recent current alcohol abuse ( regular drinking 21 unit per week male 16 unit per week female [ 1 unit = 4 cl spirit equivalent ] ) Current use nicotine containing product 5 cigarette ( equivalent ) /day and/or inability refrain use nicotine containing product study ( screen visit endofstudy visit ) . Use caffeine contain beverage 600 mg caffeine/day and/or inability refrain use caffeine contain beverage treatment period 24 h study treatment administration . Blood donation loss significant amount blood within 90 day prior first study treatment administration Administration another investigational treatment within 90 day prior first study treatment administration Unsuitable vein repeat venipuncture cannulation Predictable poor compliance inability communicate well study centre personnel Inability participate treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Alprazolam</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>